Paliperidone 3-Month Injection for Treatment of Schizophrenia: A Narrative Review
Open Access
- 21 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Psychiatry
Abstract
Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied on relapse episodes of schizophrenia include once-daily extended-release oral paliperidone (ORAL paliperidone), once-monthly paliperidone palmitate (PP1M), and once-every-3-months paliperidone palmitate (PP3M). Post-hoc analyses show that patients who were withdrawn from PP1M paliperidone had the least risk of relapse, followed by patients withdrawn from PP3M and patients withdrawn from ORAL paliperidone. PP3M was better at preventing relapse compared to ORAL paliperidone. The results demonstrated that 50% of patients who were withdrawn from ORAL paliperidone, PP1M, or PP3M remained relapse-free for ~2, 6, and 13 months, respectively. Compared to PP1M, PP3M is just as safe and effective and has the added advantage of increased adherence related to a longer dose interval, decreasing the risk of relapse.This publication has 50 references indexed in Scilit:
- Patient Outcomes Within Schizophrenia TreatmentPublished by Physicians Postgraduate Press, Inc ,2014
- Definition and description of schizophrenia in the DSM-5Schizophrenia Research, 2013
- Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophreniaSchizophrenia Research, 2012
- Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsMolecular Psychiatry, 2011
- Schizophrenia: A Concise Overview of Incidence, Prevalence, and MortalityEpidemiologic Reviews, 2008
- Epidemiology of Schizophrenia: Review of Findings and MythsPsychiatric Clinics of North America, 2007
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- SchizophreniaThe Lancet, 2004
- Relationship Between Dopamine D2 Occupancy, Clinical Response, and Side Effects: A Double-Blind PET Study of First-Episode SchizophreniaAmerican Journal of Psychiatry, 2000
- SchizophreniaThe Lancet, 1999